November 20, 2012

Tranzyme Pharma to Speak at Piper Jaffray Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that Vipin K. Garg, Ph.D., President and CEO, will speak at the 24th Annual Piper Jaffray Healthcare Conference taking place at the New York Palace hotel, New York, NY November 27-28, 2012. Tranzyme's session is scheduled for Wednesday, November 28th at 12:30 pm ET.

A live audio webcast of the presentation will be available in the "Investors" section of the Tranzyme Pharma website, www.tranzyme.com.

About Tranzyme Pharma

Tranzyme Pharma is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. While approximately 40 percent of people in the U.S. are affected by these persistent and recurring conditions which disrupt the normal movement of food throughout the GI tract, there are a limited number of safe and effective treatment options. Tranzyme is developing TZP-102, an oral ghrelin agonist for treating the symptoms associated with chronic upper GI motility disorders. Tranzyme is currently enrolling patients in a Phase 2b trial (DIGEST) evaluating TZP-102 given prior to meals in diabetic patients with gastroparesis; top-line data are expected in the first half of 2013. By leveraging its proprietary drug discovery technology, MATCH™, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical needs.

Further information about Tranzyme Pharma can be found on the Company's web site at www.tranzyme.com.

CONTACT: Corporate Inquiries:

         Susan Sharpe

         Director, Corporate Communications

         (919) 328-1109

         ssharpe@tranzyme.com



         Investor Inquiries:

         David Carey

         Lazar Partners, Ltd.

         (212) 867-1768

         dcarey@lazarpartners.com


Close window | Back to top

Copyright 2014 Ocera Therapeutics, Inc.